Evidence map›Paper›PMID 34053988›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Acute Megakaryoblastic Leukemia Harboring a Subclone Expressing BCR-ABL1 Fusion Gene Product.

Emiko Kashima, Eri Nakano, Yasuyuki Watanabe, Hiroshi Imai, Koji Oka, Shinichi Kageyama, Isao Tanaka

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Emiko KashimaDepartment of Hematology, Suzuka Kaisei Hospital, Japan.
Eri NakanoDepartment of Hematology, Suzuka Kaisei Hospital, Japan.
Yasuyuki WatanabeDepartment of Hematology, Suzuka Kaisei Hospital, Japan.
Hiroshi ImaiPathology Division, Mie University Hospital, Japan.
Koji OkaDepartment of Hematology, Suzuka Kaisei Hospital, Japan.
Shinichi KageyamaDepartment of Hematology, Suzuka Kaisei Hospital, Japan.
Isao TanakaDepartment of Hematology, Suzuka Kaisei Hospital, Japan.
Mie University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) with BCR-ABL1, also termed Philadelphia chromosome-positive AML (Ph+ AML), is a rare leukemia subtype classified by the World Health Organization in 2016. The characteristics of Ph+ AML have not been fully identified yet. We herein report a patient with Ph+ AML who phenotypically exhibited megakaryoblastic characteristics, FAB:M7 and harbored a subclone expressing BCR-ABL1 gene fusion products. This case suggests that BCR-ABL1 was acquired as a subclone due to a secondary event that might have occurred late during leukemia evolution. Our findings may aid in deciphering the mechanism underlying Ph+ AML development in future studies.

Indexed as

Leukemia, Megakaryoblastic, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablHumansFusion Proteins, bcr-ablacute megakaryoblastic leukemiaBCR-ABL1 fusion genePh+ AML

Identifiers

PMID34053988
PMCPMC8666224
OpenAlexW3164933019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.